scholarly journals Controversies in the hormonal adjuvant therapy of postmenopausal patients

2009 ◽  
Vol 11 (S1) ◽  
Author(s):  
M Dowsett
Keyword(s):  
Adjuvant Therapy ◽  
Hormonal Adjuvant Therapy

scholarly journals A Review of Studies of Hormonal Adjuvant Therapy in Prostate Cancer

1999 ◽  
Vol 36 (Suppl. 2) ◽  
pp. 14-19 ◽  
Author(s):  
M. Wirth ◽  
M. Froehner
Keyword(s):  
Prostate Cancer ◽  
Adjuvant Therapy ◽  
Hormonal Adjuvant Therapy

Adjuvant Hormone Therapy after Radical Prostatectomy: Indications and Results

1997 ◽  
Vol 83 (2) ◽  
pp. 567-575 ◽  
Author(s):  
Pasquale Ditonno ◽  
Michele Battaglia ◽  
Francesco Paolo Selvaggi
Keyword(s):  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Adjuvant Therapy ◽  
Hormonal Therapy ◽  
Residual Disease ◽  
Survival Rates ◽  
Low Grade ◽  
Adjuvant Hormonal Therapy ◽  
Adjuvant Hormone Therapy ◽  
Hormonal Adjuvant Therapy

Despite recent advances in staging modalities, nearly 30–40% of patients undergoing radical prostatectomy for clinically localized prostate cancer have residual disease. In these cases, one or more of the following conditions may be present: extracapsular disease, positive margins, invasion of the seminal vesicles, lymph node metastases or the postoperative persistence of PSA values above the biological threshold. The optimal management for residual prostate cancer remains controversial and in this setting adjuvant therapy could be appropriate. In the present review we examine the conditions in which hormonal adjuvant therapy can be indicated and the results available from retrospective or non-randomized studies. From the data in the literature and in the absence of randomized prospective studies, prudent conclusions could be drawn on the efficacy of adjuvant hormonal therapy. In cases of small volume, low grade (Gleason score «7) prostate cancer in stage C or D1, radical surgery coupled with adjuvant hormonal therapy leads to survival rates in stage C similar to those in the intraprostatic stage, and in stage D1 with minimal lymph involvement, seems to delay clinical development of metastases. Finally, the quality of life associated with adjuvant therapy and the drug regimens available for this therapy are reviewed.

Adjuvant Therapy of Breast Cancer

1994 ◽  
Vol 8 (1) ◽  
pp. 213-231 ◽  
Author(s):  
Charles L. Shapiro ◽  
I. Craig Henderson
Keyword(s):  
Breast Cancer ◽  
Adjuvant Therapy
Sign in / Sign up

Export Citation Format

Share Document